Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
暂无分享,去创建一个
M. Pfeffer | E. Braunwald | C. Cannon | D. Morrow | S. Wiviott | K. Ray
[1] A. Skene,et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. , 2005, The New England journal of medicine.
[2] Philip J. Barter,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[3] M. Pfeffer,et al. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes , 2004 .
[4] M. Pfeffer,et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.
[5] Christopher P Cannon,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[6] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[7] J. Staffa,et al. Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy , 2004, Pharmacoepidemiology and drug safety.
[8] Richard M. Moe,et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. , 2004, Journal of the American College of Cardiology.
[9] E. Topol. Intensive statin therapy--a sea change in cardiovascular prevention. , 2004, The New England journal of medicine.
[10] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[11] Thomas Weber,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[12] H. Silbershatz,et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. , 2003, The American journal of cardiology.
[13] P. Thompson,et al. Statin-associated myopathy. , 2003, JAMA.
[14] J. Shepherd,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial , 2003 .
[15] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.
[16] S. Grundy. Approach to lipoprotein management in 2001 National Cholesterol Guidelines. , 2002, The American journal of cardiology.
[17] S. Grundy,et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. , 2002, Circulation.
[18] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[19] B. Davis,et al. Safety and Tolerability of Pravastatin in Long-Term Clinical Trials: Prospective Pravastatin Pooling (PPP) Project , 2002, Circulation.
[20] E. Braunwald,et al. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. , 2002, The American journal of cardiology.
[21] Jennie Chang,et al. Cerivastatin and reports of fatal rhabdomyolysis. , 2002, The New England journal of medicine.
[22] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[23] I. Hamilton-Craig,et al. Statin‐associated myopathy , 2001, The Medical journal of Australia.
[24] S. Grundy. United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. , 2001, The American journal of cardiology.
[25] M. Ezekowitz,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.
[26] Michael F. Oliver,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.
[27] D. Black,et al. Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. , 2000, Atherosclerosis.
[28] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[29] G. Schlüter,et al. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor. , 1998, The American journal of cardiology.
[30] P. Macfarlane,et al. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). , 1998, Circulation.
[31] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[32] H. Iso,et al. Serum total cholesterol and mortality in a Japanese population. , 1994, Journal of clinical epidemiology.
[33] J. Stengård,et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.
[34] D. Jacobs,et al. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial , 1992 .
[35] D. Jacobs,et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. , 1992, Archives of internal medicine.
[36] K. Yano,et al. Serum cholesterol and mortality among Japanese-American men. The Honolulu (Hawaii) Heart Program. , 1991, Archives of internal medicine.
[37] A. Alberts,et al. Brain and optic system pathology in hypocholesterolemic dogs treated with a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. , 1988, The American journal of pathology.